xRead - Olfactory Disorders (September 2023)

20426984, 2022, 4, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22929, Wiley Online Library on [04/09/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

576

INTERNATIONAL CONSENSUS ON OLFACTION

TABLE IX-18 (Continued) Study

Year LOE Study design

Study groups CRS (n = 113)

Clinical end point Conclusions

Schriever et al 1039

2013 3

Prospective

SS-ID (16 odors)

Significant

improvement on SS-ID

Hsu

2013 3

Cohort

CRS (n = 29)

UPSIT R

≈ 50% of patient demonstrated

et al 1468

improvement in OF

Saafan

2013 2

Prospective RCT

CRSwNP (n = 17)

VAS

Significant

et al 1469

improvement on VAS

Bhandarkar et al 1470

2011

3

Observational,

CRS (n = 142)

UPSIT R

Significant

prospective cohort

improvement on UPSIT R for patients with osteitis 54.7% reported olfactory improvement of at least 4 points improvement on SS Improvement in SS in 74% of patients Significant

Soler

2010 3

Prospective

CRS (n = 101)

UPSIT R

et al 1471

Katotomichelakis 1472 2010 3

Prospective

CRSwNP (n = 116)

SS-TDI

Konstantinidis et al 1473

2010 3

Prospective

CRSwNP (n = 27)

SS-TDI

Litvack

2009 3

Prospective,

CRS (n = 111)

UPSIT R

Significant

et al 1474

multi-institutional cohort

improvement in anosmics

Salama

2009 3

Prospective cohort

CRS (n = 143)

VAS

Significant

et al 1475

improvement on VAS

Bugten

2008 3

Prospective controlled CRSwNP (n = 57) CRSsNP (n = 45)

VAS

Compared with

et al 1476

baseline, there was significant improvement on VAS in both groups No difference in degree

of improvement between groups

Konstantinidis et al 1477

2007 3

Prospective

CRSwNP (n = 18)

VAS SS

Significant

improvement in SS andVAS

Lee

2007 3

Prospective

CRSwNP (n = 60)

VAS

Significant

et al 1423

improvement in pediatric and adult groups improvement in geriatric population prednisone group, the ESSgroup demonstrated significant improvement in symptom score at 6 months

No significant

Alobid

Subjective symptom score (0-3)

Compared with the

2005 2

RCT

CRSwNP (n = 109) ESS followed by 12 months of intranasal budesonide Prednisone × 2weeks followed by 12 months of intranasal budesonide

et al 1478

No difference at 12 months

(Continues)